MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s13555-025-01450-x

Медицинская библиотека · Dermatology and therapy · 2025

Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.

Cai Lin, Li Chengxin, Li Shanshan, Zhang Xiaodong, Wang Gang, Yu Jianbin, Huang Kun, Fang Hong, Ding Yangfeng, Wang Jinyan, Jiang Congjun, Lu Qianjin, Tao Juan, Zhang Jianzhong

СтатьяПеревод пока не подготовлен

Аннотация

INTRODUCTION

Psoriasis is a chronic inflammatory skin disease. This study evaluated the efficacy and safety of xeligekimab (GR1501), a novel anti-interleukin-17A (anti-IL-17A) monoclonal antibody, in Chinese patients with moderate-to-severe plaque psoriasis.

METHODS

In this multicenter, randomized, double-blind, phase II trial, 199 patients were assigned (1:1:1:1) to receive placebo (n = 49) or xeligekimab 100 mg (n = 50), 150 mg (n = 49), or 200 mg (n = 51) every 4 weeks for 12 weeks. All participants then entered a 40-week extension receiving xeligekimab 200 mg every 4 or 8 weeks. The primary endpoint was a 75% reduction in the Psoriasis Area and Severity Index (PASI 75) at week 12. Secondary endpoints included PASI 75, PASI 90 (≥ 90% improvement), and a static Physician's Global Assessment (sPGA) score of 0/1 (clear/almost clear) at week 52. Safety, pharmacokinetics (PK), and anti-drug antibodies (ADA) were also assessed.

RESULTS

At week 12, PASI 75 response rates for the 100, 150, and 200 mg groups were 86.0%, 89.8%, and 88.2%, respectively, versus 2.0% for placebo (P < 0.05). At week 52, PASI 75, PASI 90, and sPGA 0/1 response rates remained high in both 4-week (98.8%, 83.3%, 77.4%) and 8-week (92.9%, 83.3%, 78.6%) groups. No dose-dependent safety issues or ADA positivity were observed.

CONCLUSION

Xeligekimab demonstrated strong efficacy, sustained response, and favorable safety in patients with moderate-to-severe plaque psoriasis.

TRIAL REGISTRATION NUMBER: ChiCTR1800017956.

Для цитирования: Cai Lin, Li Chengxin, Li Shanshan, Zhang Xiaodong, Wang Gang, Yu Jianbin, Huang Kun, Fang Hong, Ding Yangfeng, Wang Jinyan, Jiang Congjun, Lu Qianjin, Tao Juan, Zhang Jianzhong. Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial.. Dermatology and therapy. 2025. DOI: 10.1007/s13555-025-01450-x.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.